TechNotes

Learn more about our WAVEsystem and its applications

  • TechNote

    Pushing the boundaries in pharmaceutical hit discovery with the novel waveRAPID® kinetic assay

    In this TechNote, conducted by an HTS drug discovery group of our customer Idorsia Pharmaceuticals Ltd, we demonstrate the power of waveRAPID in streamlining the kinetic characterization of large numbers of drug hit compounds, with results comparable to traditional SPR and high reproducibility.

  • TechNote

    Screening of crude reaction mixtures

    In this TechNote we show how the WAVEsystem provides a reliable environment to support optimisation of hits in fragment-based drug discovery. With high sensitivity and robust microfluidics, the WAVEsystem offers kinetic data in excellent agreement with Biacore T200 measurements. This is illustrated through a retrospectively measured Vernalis campaign to identify selective, potent inhibitors of Pyruvate Dehydrogenase Kinase 2 (PDHK2) and Heat Shock Protein 90 (HSP90).

  • TechNote

    Sensitive kinetic analysis of small molecules binding to large drug targets

    In this TechNote we show how the WAVEsystem can be used to accurately monitor binding kinetics of large target-to-analyte molecular weight (MW) ratios (>300:1), thanks to the expanded sensing field over which the Grating-Coupled Interferometry (GCI) technology measures for high sensitivity.

  • TechNote

    Highly accurate resolution of fast off-rates to significantly reduce false-positives

    In this TechNote we show how the WAVEsystem can be used to accurately measure fast off-rate kinetics of weakly binding molecules. Thanks to a cartridge design that enables ultra-fast transition times of 150 ms, low potency hits can now be easily spotted for more successful drug discovery.

  • TechNote

    Highly sensitive analysis at low immobilization levels, without mass transport limitation Kinetics below Rmax 1

    In this TechNote we show the remarkable sensitivity of the WAVEsystem. Thanks to the expanded sensing field over which the Grating-Coupled Interferometry (GCI) technology measures, high-resolution kinetic determination at even very low responses is possible, potentially reducing material costs significantly.

  • TechNote

    Binding kinetics of a GPCR

    Membrane proteins are notoriously difficult to study due to the requirement for a membrane-mimicking environment and their instability once extracted from a cellular membrane. Here we show the capability of the WAVE to measure the interaction of a peptide ligand agonist (NTA11) with a thermostabilized variant of the neurotensin receptor 1 (NTSR1) at highest resolution.

  • TechNote

    Affinity and kinetics of antibodies in serum

    In this TechNote we show how the WAVE system can be used to accurately determine kinetics in serum. Thanks to a no-clog microfluidic design, kinetic studies can be performed under conditions that mimic the native environment as closely as possible, enabling the translation of these results to the clinic.

  • TechNote

    Quick characterization of binding onto unpurified GPCRs

    In this TechNote, we show how the WAVEsystem can be used for the kinetic analysis of G-protein binding onto detergent-solubilized, unpurified GPCRs. By shortening a typical 10-step purification process, this method requires significantly less material (30mL of cell culture) and less time (less than 1 hour), thereby offering an alternative for screening purposes at an early stage of the drug discovery process involving membrane proteins.

  • TechNote

    Antibody characterization from COVID-19 patient plasma binding to SARS-CoV-2 antigens

    In this TechNote, we show how the WAVEsystem can be used for the characterization of binding affinity and kinetics of antibodies raised against SARSCoV-2 in clinical human blood plasma samples. With innovative disposable, no-clog microfluidics and high sensitivity, the WAVEsystem opens the door for antibody characterization directly from clinical blood plasma samples. The methods described here are also compatible with high concentrations of serum and plasma of SARS-CoV-2 patients’ samples.

  • TechNote

    Shedding light on Sybody® candidates binding onto SARS-CoV-2 spike RBD

    In this TechNote we show how the WAVE system can be used to understand the binding dynamics of Sybody® candidates to the receptor binding domain (RBD) of SARS-CoV-2, both provided by Linkster Therapeutics AG and the University of Zürich. With high sensitivity and robust microfluidics, the WAVEsystem is suitable for competition assays, confirming and enriching ELISA data. By providing a rapid kinetic characterization for inhibition assays, with ACE2 kindly provided by leadXpro, the WAVE is accelerating the development of therapeutics against SARS-CoV-2.

  • TechNote

    Pushing the boundaries in pharmaceutical hit discovery with the novel waveRAPID® kinetic assay

    In this TechNote, conducted by an HTS drug discovery group of our customer Idorsia Pharmaceuticals Ltd, we demonstrate the power of waveRAPID in streamlining the kinetic characterization of large numbers of drug hit compounds, with results comparable to traditional SPR and high reproducibility.

  • TechNote

    Sensitive kinetic analysis of small molecules binding to large drug targets

    In this TechNote we show how the WAVEsystem can be used to accurately monitor binding kinetics of large target-to-analyte molecular weight (MW) ratios (>300:1), thanks to the expanded sensing field over which the Grating-Coupled Interferometry (GCI) technology measures for high sensitivity.

  • TechNote

    Highly accurate resolution of fast off-rates to significantly reduce false-positives

    In this TechNote we show how the WAVEsystem can be used to accurately measure fast off-rate kinetics of weakly binding molecules. Thanks to a cartridge design that enables ultra-fast transition times of 150 ms, low potency hits can now be easily spotted for more successful drug discovery.

  • TechNote

    Highly sensitive analysis at low immobilization levels, without mass transport limitation Kinetics below Rmax 1

    In this TechNote we show the remarkable sensitivity of the WAVEsystem. Thanks to the expanded sensing field over which the Grating-Coupled Interferometry (GCI) technology measures, high-resolution kinetic determination at even very low responses is possible, potentially reducing material costs significantly.

  • TechNote

    Binding kinetics of a GPCR

    Membrane proteins are notoriously difficult to study due to the requirement for a membrane-mimicking environment and their instability once extracted from a cellular membrane. Here we show the capability of the WAVE to measure the interaction of a peptide ligand agonist (NTA11) with a thermostabilized variant of the neurotensin receptor 1 (NTSR1) at highest resolution.

  • TechNote

    Affinity and kinetics of antibodies in serum

    In this TechNote we show how the WAVE system can be used to accurately determine kinetics in serum. Thanks to a no-clog microfluidic design, kinetic studies can be performed under conditions that mimic the native environment as closely as possible, enabling the translation of these results to the clinic.

  • TechNote

    Quick characterization of binding onto unpurified GPCRs

    In this TechNote, we show how the WAVEsystem can be used for the kinetic analysis of G-protein binding onto detergent-solubilized, unpurified GPCRs. By shortening a typical 10-step purification process, this method requires significantly less material (30mL of cell culture) and less time (less than 1 hour), thereby offering an alternative for screening purposes at an early stage of the drug discovery process involving membrane proteins.

  • TechNote

    Antibody characterization from COVID-19 patient plasma binding to SARS-CoV-2 antigens

    In this TechNote, we show how the WAVEsystem can be used for the characterization of binding affinity and kinetics of antibodies raised against SARSCoV-2 in clinical human blood plasma samples. With innovative disposable, no-clog microfluidics and high sensitivity, the WAVEsystem opens the door for antibody characterization directly from clinical blood plasma samples. The methods described here are also compatible with high concentrations of serum and plasma of SARS-CoV-2 patients’ samples.

  • TechNote

    Shedding light on Sybody® candidates binding onto SARS-CoV-2 spike RBD

    In this TechNote we show how the WAVE system can be used to understand the binding dynamics of Sybody® candidates to the receptor binding domain (RBD) of SARS-CoV-2, both provided by Linkster Therapeutics AG and the University of Zürich. With high sensitivity and robust microfluidics, the WAVEsystem is suitable for competition assays, confirming and enriching ELISA data. By providing a rapid kinetic characterization for inhibition assays, with ACE2 kindly provided by leadXpro, the WAVE is accelerating the development of therapeutics against SARS-CoV-2.